Inhaled Corticosteroids And Risk Of Tuberculosis In Patients With Obstructive Lung Diseases: A Systematic Review And Meta-Analysis Of Non-randomized Studies

References

• World Health Organization. Global Tuberculosis Report 2018; 2018 Available from: https://www.who.int/tb/publications/global_report/en/. Accessed 9, 2018.
   Google Scholar
• World Health Organization. Global strategy and targets for tuberculosis prevention, care and control after 2015; 2015 Available from: http://www.who.int/tb/post2015_strategy/en/. Accessed 9, 2018.
   Google Scholar
• Clancy L, Rieder HL, Enarson DA, Spinaci S. Tuberculosis elimination in the countries of Europe and other industrialized countries. Eur Respir J. 1991;4(10):1288–1295.1804678
   PubMed Web of Science ®Google Scholar
• Broekmans JF, Migliori GB, Rieder HL, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J. 2002;19(4):765–775. doi:10.1183/09031936.02.0026140211999007
   PubMed Web of Science ®Google Scholar
• Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016;5:e10. doi:10.1038/emi.2016.11926839146
   PubMed Web of Science ®Google Scholar
• Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology. 2010;15(4):603–622. doi:10.1111/j.1440-1843.2010.01751.x20409026
   PubMed Web of Science ®Google Scholar
• World Health Organization. Priorities for tuberculosis research; 2013 Available from: http://apps.who.int/iris/handle/10665/85888. Accessed 9, 2018.
   Google Scholar
• American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161(4):S221–47. doi:10.1164/ajrccm.161.6.990909810764341
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention; 2018 Available from: https://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/. Accessed, 9 2018.
   Google Scholar
• Singh D, Agusti A, Anzueto A. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J;2019 1900164. doi:10.1183/13993003.00164-201930846476
   PubMed Web of Science ®Google Scholar
• Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029–1036. doi:10.1136/thoraxjnl-2012-20287224130228
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009;373(9678):1905–1917. doi:10.1016/S0140-6736(09)60326-319482216
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131(3):636–645. doi:10.1016/j.jaci.2012.12.156423360759
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Inhaled corticosteroids. Pharmaceuticals (Basel). 2010;3(3):514–540. doi:10.3390/ph303051427713266
   PubMedGoogle Scholar
• Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006;55(1):19–26. doi:10.1002/art.2170516463407
   PubMed Web of Science ®Google Scholar
• Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin North Am. 2016;42(1):157–176. doi:10.1016/j.rdc.2015.08.00426611557
   PubMed Web of Science ®Google Scholar
• Dong YH, Chang CH, Wu FL, et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: a systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials. Chest. 2014;145(6):1286–1297. doi:10.1378/chest.13-213724504044
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65–W94. doi:10.7326/0003-4819-151-4-200908180-0013619622512
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute. Quality assessment tool for observational cohort and cross-sectional studies. quality assessment of case-control studies. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed, 9 2018.
   Google Scholar
• Higgins JPT, Green S Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration; 2011 [updated 3, 2011]. Available from: www.handbook.cochrane.org. Accessed 917, 2019.
   Google Scholar
• World Health Organization, Health statistics and information systems. Metrics: population attribuitable fraction (PAF). Available from: https://www.who.int/healthinfo/global_burden_disease/metrics_paf/en/. Accessed 2, 2019.
   Google Scholar
• Wang Z. Converting odds ratio to relative risk in cohort studies with partial data information. J Stat Softw. 2013;55(5);1–11. doi:10.18637/jss.v055.i05
   Web of Science ®Google Scholar
• Brassard P, Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med. 2011;183(5):675–678. doi:10.1164/rccm.201007-1099OC20889902
   PubMed Web of Science ®Google Scholar
• Chung WS, Chen YF, Hsu JC, Yang WT, Chen SC, Chiang JY. Inhaled corticosteroids and the increased risk of pulmonary tuberculosis: a population-based case-control study. Int J Clin Pract. 2014;68(10):1193–1199. doi:10.1111/ijcp.1245924838040
   PubMed Web of Science ®Google Scholar
• Jian ZH, Huang JY, Lin FC, et al. Post-inhaled corticosteroid pulmonary tuberculosis increases lung cancer in patients with asthma. PLoS One. 2016;11(7):e0159683. doi:10.1371/journal.pone.015968327448321
   PubMed Web of Science ®Google Scholar
• Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax. 2013;68(12):1105–1113. doi:10.1136/thoraxjnl-2012-20317523749841
   PubMed Web of Science ®Google Scholar
• Wu MF, Jian ZH, Huang JY, et al. Post-inhaled corticosteroid pulmonary tuberculosis and pneumonia increases lung cancer in patients with COPD. BMC Cancer. 2016;16(1):778. doi:10.1186/s12885-016-2838-427724847
   PubMed Web of Science ®Google Scholar
• Kim JH, Park JS, Kim KH, Jeong HC, Kim EK, Lee JH. Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest. 2013;143(4):1018–1024. doi:10.1378/chest.12-122523079688
   PubMed Web of Science ®Google Scholar
• Shu CC, Wu HD, Yu MC, et al. Use of high-dose inhaled corticosteroids is associated with pulmonary tuberculosis in patients with chronic obstructive pulmonary disease. Medicine (Baltimore). 2010;89(1):53–61. doi:10.1097/MD.0b013e3181cafcd320075705
   PubMed Web of Science ®Google Scholar
• Brode SK, Campitelli MA, Kwong JC, et al. The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur Respir J. 2017;50(3):1700037. doi:10.1183/13993003.00711-201728931659
   PubMed Web of Science ®Google Scholar
• Yeh JJ, Wang YC, Kao CH. Asthma-chronic obstructive pulmonary diseases overlap syndrome increases the risk of incident tuberculosis: a national cohort study. PLoS One. 2016;11(7):e0159012. doi:10.1371/journal.pone.015901227448309
   PubMed Web of Science ®Google Scholar
• Burgel PR, Deslée G, Jebrak G, et al. Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011? Eur Respir J. 2014;43(4):1201–1203. doi:10.1183/09031936.0016231324176996
   PubMed Web of Science ®Google Scholar
• James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858.30496104
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159(9):941–955. doi:10.1001/archinte.159.9.94110326936
   PubMed Web of Science ®Google Scholar
• Iannella H, Luna C, Waterer G. Inhaled corticosteroids and the increased risk of pneumonia: what’s new? A 2015 updated review. Ther Adv Respir Dis. 2016;10(3):235–255. doi:10.1177/175346581663020826893311
   PubMed Web of Science ®Google Scholar
• Yang M, Chen H, Zhang Y, et al. Long-term use of inhaled corticosteroids and risk of upper respiratory tract infection in chronic obstructive pulmonary disease: a meta-analysis. Inhal Toxicol. 2017;29(5):219–226. doi:10.1080/08958378.2017.134600628714745
   PubMed Web of Science ®Google Scholar
• Campos-Outcalt DE. Accuracy of ICD-9-CM codes in identifying reportable communicable diseases. Qual Assur Util Rev. 1990;5(3):86–89.2136670
   PubMedGoogle Scholar
• Barber C, Lacaille D, Fortin PR. Systematic review of validation studies of the use of administrative data to identify serious infections. Arthritis Care Res (Hoboken). 2013;65(8):1343–1357. doi:10.1002/acr.2195923335588
   PubMed Web of Science ®Google Scholar
• World Health Organization. Tuberculosis country profiles; 2018 Available from: http://www.who.int/tb/country/data/profiles/en/. Accessed 9, 2018.
   Google Scholar
• Centers for disease control, ministry of health and welfare, Republic of China. Taiwan Tuberculosis Control Report 2013. 4 2014 Available from: https://www.cdc.gov.tw/english/infectionreportinfo.aspx?treeid=3847719104be0678&nowtreeid=ffb51203f16bfe57&tid=98263CEFADF0DAE7. Accessed 9, 2018.
   Google Scholar
• European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2018 – 2016 data. Available from: https://ecdc.europa.eu/en/publications-data/tuberculosis-surveillance-and-monitoring-europe-2018. Accessed 9, 2018.
   Google Scholar
• Lönnroth K, Castro KG, Chakaya JM, et al. Tuberculosis control and elimination 2010–50: cure, care, and social development. lancet. 2010;375(9728):1814–1829. doi:10.1016/S0140-6736(10)60483-720488524
   PubMed Web of Science ®Google Scholar
• Yii AC, Soh AZ, Chee CBE, et al. Asthma, sinonasal disease, and the risk of active tuberculosis. J Allergy Clin Immunol Pract. 2019;7(2):641–648.e1. doi:10.1016/j.jaip.2018.07.03630130591
   PubMed Web of Science ®Google Scholar
• Andréjak C, Nielsen R, Thomsen VØ, Duhaut P, Sørensen HT, Thomsen RW. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013;68(3):256–262. doi:10.1136/thoraxjnl-2012-20177222781123
   PubMed Web of Science ®Google Scholar
• Ni S, Fu Z, Zhao J, Liu H. Inhaled corticosteroids (ICS) and risk of mycobacterium in patients with chronic respiratory diseases: a meta-analysis. J Thorac Dis. 2014;6(7):971–978. doi:10.3978/j.issn.2072-1439.2014.07.0325093095
   PubMed Web of Science ®Google Scholar